Post by
Ciao on Feb 04, 2024 5:37pm
No partners are suitable for CEAPRO: case study CoQ10
In the Oct. 2022 NR extolling the success of CoQ10 bioavailbility studies (after years of pivoting from BG);
“With our recent announcement of the successful development and publication of new chemical conjuguates like PGX Alginate loaded with CoQ10, we are very pleased to have demonstrated invivo a superior bioavailabilty for these new chemical complexes with CoQ10 even when it is mixed in water formulation where bioavailabilty has always been a challenge for most commercial CoQ10 supplements. Knowing that Ceapro’s PGX-processed carriers can deliver CoQ10 into the tissues, we will advance to the next stage which includes looking for efficacy of these new chemical entities along with a partner involved in the marketing and sales of various forms of delivery systems that can be included in food, drinks, cream formulations, medical supplies like thin films, skin patches and up to nutraceuticals and pharmaceuticals,” said Gilles Gagnon, M.Sc., MBA, President and CEO.
A CoQ10 licensing agreement was set as a target for H2 2023 (conveniently after the AGM) to which nothing has been announced, except for the non-annoucement that the CRO that was hired had left after leading "serious" discussions.
OATS we need a capable CEO who can lead discussions with a commercial partner to close a PGX licensing deal. If such a deal was inked in 2023 where do you think the share price or market cap of the company would be, definitely not sub .20 or under a laughable $14M (with $10M in cash) but likely north of $1 with a market cap of $100M.